Kos Pharmaceuticals
10
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 10 trials
100.0%
+13.5% vs industry average
90%
9 trials in Phase 3/4
10%
1 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
Pioglitazone vs Placebo in Combination With Niacin Extended Release on Low HDL
Role: collaborator
Benefit of Elevation of HDL-C on Cardiovascular Outcomes in Women
Role: collaborator
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Role: lead
Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
Role: lead
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
Role: lead
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
Role: lead
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
Role: lead
Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
Role: collaborator
Carotid Atherosclerosis Regression at Magnetic Resonance Assessment.
Role: collaborator
Study of Niacin and Rosiglitazone in Dysmetabolic Dyslipidemia
Role: collaborator
All 10 trials loaded